Multiple System Atrophy Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

Delveinsight Business Research LLP

“Multiple System Atrophy Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Multiple System Atrophy Market. 

The Multiple System Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Multiple System Atrophy Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for the treatment of Multiple System Atrophy and the aggregate therapies developed by major pharma companies.

• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Multiple System Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Mechanism of Action of the Emerging Pipeline Therapies

• Peroxidase inhibitors

• Chelating agents

• Adrenergic receptor agonists

• Gene transference

• Monoamine oxidase B inhibitors

• Alpha-synuclein inhibitors

• Bcr-abl tyrosine kinase inhibitors

Latest Key Developments in the Multiple System Atrophy Therapeutics Market

On May 9, 2023, Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).

Learn How the Ongoing Clinical & Commercial Activities will Affect the Multiple System Atrophy Therapeutic Segment @

https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight

Multiple System Atrophy Therapeutics Landscape

There is no specific treatment for MSA. Treatment is aimed at controlling the symptoms of the disease. Drugs that are used to treat people with Parkinson’s disease, most notably levodopa (given in tablets of Sinemet), may also be prescribed for individuals with MSA. In addition to levodopa, other drugs used to treat Parkinson’s disease may be used to treat individuals with MSA.

There are approx. 20+ key companies developing therapies for Multiple System Atrophy. Currently, Biohaven Pharmaceuticals is leading the therapeutics market with its Multiple System Atrophy drug candidates in the most advanced stage of clinical development.

The Leading Players in the Multiple System Atrophy Therapeutics Market Include

• AC Immune

• Alterity Therapeutics

• Asklepios BioPharmaceutical

• Biogen

• Biohaven Pharmaceuticals

• Blade Therapeutics

• Brain Neurotherapy Bio, Inc.

• Corestem, Inc.

• FAScinate Therapeutics

• H Lundbeck A/S

• Inhibikase Therapeutics

• Ionis Pharmaceuticals, Inc.

• Lundbeck A/S

• Modag

• Neuramedy

• ProMIS Neurosciences

• RETROTOPE

• Stealth BioTherapeutics

• Theravance Biopharma

• Vaxxinity

• Wren Therapeutics

And Many Others

Multiple System Atrophy Emerging and Marketed Drugs Covered in the Report Include:

• AAV2-GDNF gene therapy: Brain Neurotherapy Bio, Inc

• Ampreloxetine (TD-9855): Theravance Biopharma

• ATH434: Alterity Therapeutics

• CS10BR05: Corestem

• Emeramide: EmeraMed

• Lu AF82422: Lundbeck A/S

• Research programme CNS Gene Therapy: AskBio

• Safinamide: Zambon SpA

• SBT 272: Stealth BioTherapeutics

• Stabilized PUFAs: Retrotope

• Verdiperstat: Biohaven Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Multiple System Atrophy Current Treatment Patterns

4. Multiple System Atrophy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Multiple System Atrophy Late Stage Products (Phase-III)

7. Multiple System Atrophy Mid-Stage Products (Phase-II)

8. Multiple System Atrophy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Multiple System Atrophy Discontinued Products

13. Multiple System Atrophy Product Profiles

14. Key Companies in the Multiple System Atrophy Market

15. Key Products in the Multiple System Atrophy Therapeutics Segment

16. Dormant and Discontinued Products

17. Multiple System Atrophy Unmet Needs

18. Multiple System Atrophy Future Perspectives

19. Multiple System Atrophy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services and Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/